Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent Lipid Nanoparticle siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid enabling highly efficient siRNA and mRNA delivery via lipid nanoparticles (LNPs) [Rafiei et al., 2025]. Its pH-dependent charge transition facilitates endosomal escape while minimizing systemic toxicity [Related]. The compound achieves ~1000-fold greater potency in hepatic gene silencing compared to its predecessor DLin-DMA [APExBIO]. Dlin-MC3-DMA is foundational in machine learning-guided LNP design for immunomodulatory mRNA therapy [Rafiei et al., 2025]. Storage, solubility, and formulation parameters are critical for optimal performance.

Biological Rationale

Efficient delivery of genetic payloads such as siRNA and mRNA is essential for realizing the therapeutic potential of gene silencing and protein replacement strategies. Direct administration of naked nucleic acids is hindered by rapid enzymatic degradation, poor cellular uptake, and systemic clearance [Rafiei et al., 2025]. Lipid nanoparticles (LNPs) provide a protective, customizable vehicle for these molecules. Dlin-MC3-DMA is a next-generation ionizable cationic lipid that solves key limitations of earlier LNP systems by offering low toxicity, high encapsulation efficiency, and potent endosomal escape [Benchmark Article]. Its inclusion in LNPs enables both hepatic gene silencing and tissue-targeted immunomodulation, as validated in preclinical and translational workflows [Rafiei et al., 2025].

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is a synthetic lipid with a tertiary amine group that is protonated at acidic pH (~pH 5-6) but remains neutral at physiological pH (7.4). This pH-dependent ionization underpins two critical mechanisms:

• Endosomal Escape: After cellular uptake via endocytosis, the acidic endosomal environment protonates Dlin-MC3-DMA, converting it to a cationic state. This triggers membrane destabilization, facilitating release of nucleic acids into the cytoplasm [Rafiei et al., 2025].
• Reduced Systemic Toxicity: At neutral pH, Dlin-MC3-DMA is uncharged, minimizing interactions with non-target tissues and reducing off-target effects [APExBIO].

When formulated with helper lipids (DSPC), cholesterol, and PEGylated lipids (such as PEG-DMG), Dlin-MC3-DMA forms stable LNPs optimized for nucleic acid encapsulation and delivery. Machine learning approaches now enable the systematic tuning of LNP composition for specific cell types and immunological states [Rafiei et al., 2025]. For a detailed breakdown of the physicochemical basis of endosomal escape, see this mechanistic analysis, which clarifies how this article expands on predictive modeling for translational applications.

Evidence & Benchmarks

• Dlin-MC3-DMA exhibits approximately 1000-fold greater potency for hepatic gene silencing of Factor VII in mice compared to DLin-DMA, with an ED₅₀ of 0.005 mg/kg [APExBIO].
• In non-human primates, Dlin-MC3-DMA achieves transthyretin (TTR) gene silencing with an ED₅₀ of 0.03 mg/kg [Rafiei et al., 2025].
• LNP formulations containing Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG are optimized for high encapsulation efficiency (>90%) and rapid mRNA release in vitro [Rafiei et al., 2025].
• Machine learning-guided design has enabled the development of HA-modified Dlin-MC3-DMA LNPs for targeted immunomodulation of hyperactivated microglia, as shown by reduced TNF-α and increased IL-10 in BV-2 and iPSC-derived microglia models [Rafiei et al., 2025].
• Dlin-MC3-DMA is insoluble in water and DMSO, but soluble in ethanol at ≥152.6 mg/mL, critical for LNP formulation [APExBIO].

Applications, Limits & Misconceptions

Dlin-MC3-DMA is primarily employed in:

• Hepatic gene silencing: Used extensively in siRNA therapeutics targeting liver-expressed genes (e.g., Factor VII, TTR) [Rafiei et al., 2025].
• mRNA vaccine formulation: Underpins several COVID-19 and experimental vaccines due to robust mRNA payload delivery [Rafiei et al., 2025].
• Immunomodulatory and cancer immunochemotherapy research: Enables delivery of immunoregulatory mRNAs to specific immune cell subtypes [Pioneering Article]. This article clarifies LNP design strategies for neuroinflammatory targeting, extending prior discussions of hepatic applications.

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water-soluble: Attempting to dissolve in aqueous buffers leads to precipitation and loss of activity.
• Unsuitable for direct nucleic acid delivery without LNP formulation: The lipid must be part of a nanoparticle system for efficacy.
• Charge state is pH-dependent: At physiological pH, the lipid is neutral, so it does not promote cell entry or endosomal escape outside acidic compartments.
• Storage conditions are critical: Degradation occurs rapidly at room temperature or upon repeated freeze-thaw cycles; always store at -20°C or below and use solutions immediately.
• Potency is context-dependent: Efficacy may be lower in non-hepatic or non-optimized in vivo models; machine learning-guided optimization is recommended for new targets.

Workflow Integration & Parameters

The A8791 Dlin-MC3-DMA kit from APExBIO is supplied for research use. Key workflow considerations include:

• Solubility: Dissolve only in ethanol (≥152.6 mg/mL). Avoid water and DMSO.
• Formulation: Standard LNPs combine Dlin-MC3-DMA with DSPC, cholesterol, and PEG-DMG. Typical molar ratios: 50:10:38.5:1.5 for ionizable lipid:DSPC:cholesterol:PEG-lipid [Benchmark Article].
• Mixing: Use microfluidic or rapid mixing techniques for uniform nanoparticle size distribution (60–100 nm).
• Storage: Keep compound at -20°C or below; prepare working solutions fresh.
• Payload Loading: Typical nucleic acid:lipid ratios (N/P) range from 3:1 to 6:1, depending on payload and cell type.
• Quality Control: Confirm encapsulation efficiency (>90%) and particle size by DLS or NTA.

For troubleshooting and advanced formulation strategies, see this in-depth guide, which updates previous reports with predictive analytics and machine learning integration.

Conclusion & Outlook

Dlin-MC3-DMA represents a benchmark ionizable cationic liposome for robust and safe lipid nanoparticle-mediated siRNA and mRNA delivery. Its unique pH-dependent behavior and high potency have enabled advances in hepatic gene silencing, immunotherapy, and mRNA vaccine platforms. The integration of machine learning for LNP design is expanding the utility of Dlin-MC3-DMA to cell-specific and immunomodulatory applications [Rafiei et al., 2025]. For the latest protocols and purchasing information, refer to APExBIO’s official product page.